Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Stock analysts at Cantor Fitzgerald raised their FY2017 earnings per share (EPS) estimates for Endo International PLC in a research note issued on Sunday. Cantor Fitzgerald analyst L. Chen now expects that the company will earn $3.64 per share for the year, up from their prior forecast of $3.35. Cantor Fitzgerald has a “Neutral” rating and a $7.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Endo International PLC’s FY2018 earnings at $3.11 EPS.

Other research analysts also recently issued reports about the company. Royal Bank Of Canada reissued a “sector perform” rating and issued a $9.00 price objective (down from $15.00) on shares of Endo International PLC in a research note on Wednesday, August 9th. Morgan Stanley dropped their price target on Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 10th. Deutsche Bank AG set a $13.00 price target on Endo International PLC and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research downgraded Endo International PLC from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. Finally, Citigroup Inc. dropped their price target on Endo International PLC from $9.00 to $7.00 and set a “neutral” rating on the stock in a research note on Friday, November 10th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have issued a buy rating to the stock. Endo International PLC currently has a consensus rating of “Hold” and a consensus price target of $11.67.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/15/research-analysts-offer-predictions-for-endo-international-plcs-fy2017-earnings-endp.html.

Shares of Endo International PLC (NASDAQ ENDP) opened at $6.99 on Wednesday. Endo International PLC has a 52-week low of $5.77 and a 52-week high of $18.23. The company has a market capitalization of $1,493.97, a PE ratio of 1.38 and a beta of 0.53. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. Endo International PLC had a positive return on equity of 66.98% and a negative net margin of 126.97%. The firm had revenue of $786.90 million for the quarter, compared to analyst estimates of $794.93 million. During the same quarter in the previous year, the company posted $1.01 EPS. The business’s revenue was down 11.0% on a year-over-year basis.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gamco Investors INC. ET AL grew its stake in shares of Endo International PLC by 5.6% during the second quarter. Gamco Investors INC. ET AL now owns 62,700 shares of the company’s stock valued at $700,000 after buying an additional 3,300 shares during the last quarter. James Investment Research Inc. bought a new position in shares of Endo International PLC during the second quarter valued at about $113,000. Russell Investments Group Ltd. grew its stake in shares of Endo International PLC by 20.9% during the second quarter. Russell Investments Group Ltd. now owns 325,860 shares of the company’s stock valued at $3,640,000 after buying an additional 56,407 shares during the last quarter. Sivik Global Healthcare LLC bought a new position in shares of Endo International PLC during the second quarter valued at about $2,793,000. Finally, Columbia Partners L L C Investment Management bought a new position in shares of Endo International PLC during the second quarter valued at about $1,257,000. Institutional investors and hedge funds own 90.50% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Earnings History and Estimates for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.